Catalyst Biosciences, Inc.

As of May 9, 2025, Catalyst Biosciences, Inc. is considered overvalued due to its high P/E ratio of 94 and significant underperformance with a year-to-date return of -36.45%, compared to the S&P 500's 12.22%.

As of June 17, 2025, Catalyst Biosciences, Inc. is considered overvalued with a P/E ratio of 94 and an EV to EBITDA of 57.11, significantly higher than industry averages, and has underperformed the S&P 500 with a year-to-date return of -35.79%.

As of June 9, 2025, the trend is mildly bearish due to bearish weekly MACD and moving averages, though some underlying strength is indicated by the monthly MACD and Dow Theory.

As of March 2022, the management team of Catalyst Biosciences, Inc. includes Mr. Augustine Lawlor (Independent Chairman), Dr. Nassim Usman (CEO), and several independent directors: Dr. Errol De Souza, Ms. Andrea Hunt, Dr. Geoffrey Ling, Ms. Sharon Tetlow, and Mr. Edward Williams. This team provides governance and strategic direction for the company.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions. As of March 2025, it reported net sales of $22 million and a net profit of $4 million, with a market cap of $694.30 million.

As of Jun 18, Catalyst Biosciences, Inc. has a market capitalization of 694.30 million, with net sales of 100.65 million and a net profit of 11.70 million reported over the latest four quarters.